Follow-The-Filings

Security · featured owners

PHAT Phathom Pharmaceuticals Inc.

Health Care COM Equity as of 2026 Q2 among managers we track

  • 2 Owners
  • Max 0.4%
  • $4M
  • 1 new 1 reduce

Who owns this now

Largest portfolio weights among featured holders · max 0.4% (David Witzke - Avidity Partners Management) · not free-float ownership

  1. David Witzke reduce 0.35%
  2. James Silverman new 0.18%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
David Witzke - Avidity Partners Management 2026 Q2 0.35% Reduce −19.8% 200,000 $2M history
James Silverman - Opaleye Management 2026 Q2 0.18% New 0.18% 185,589 $2M history

2 current · options excluded

SEC filings

Recent issuer filings from EDGAR · 14 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 8.01 Filing Doc
8-K 5.07 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEFA14A Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
424B5 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
424B5 Filing Doc
8-K 8.01 Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 15 rows shown

Filed Form Detail Links
4 Period Sep 3, 2026 Filing Doc
4 Period Jul 14, 2026 Filing Doc
4 Period May 22, 2026 Filing Doc
4 Period May 19, 2026 · 7 forms Filing Doc
4 Period Mar 10, 2026 Filing Doc
4 Period Feb 27, 2026 Filing Doc
4 Period Feb 10, 2026 · 2 forms Filing Doc
4 Period Jan 23, 2026 Filing Doc
4 Period Jan 21, 2026 Filing Doc
4 Period Jan 13, 2026 Filing Doc
4 Period Jan 2, 2026 · 3 forms Filing Doc
4 Period Dec 19, 2025 Filing Doc
4 Period Dec 17, 2025 · 2 forms Filing Doc
4 Period Dec 18, 2025 Filing Doc
4 Period Nov 28, 2025 Filing Doc

Updated 4 days ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $0.682M $55.25M $175.11M
Gross profit $0.515M $47.28M $152.51M
Gross margin * 75.5% 85.6% 87.1%
Net income -$201.59M -$334.33M -$221.25M
Net margin * -29558.9% -605.1% -126.3%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $397.43M $360.13M $228.97M
Total non-current assets * $16.41M $18.18M $30.18M
Total assets $413.84M $378.32M $259.15M
Total current liabilities $38.78M $85.73M $132.04M
Total non-current liabilities * $447.82M $546.17M $565.27M
Total equity -$72.76M -$253.58M -$438.17M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$137.58M -$266.77M -$166.78M
Cash from investing -$1.63M -$0.135M -$0.229M
Cash from financing $367.58M $182.77M -$0.288M
Net change in cash $228.37M -$84.13M -$167.29M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders